NCT03059992Phase 3Completed

Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment

Study sponsor: Scynexis, Inc. · SCYX

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2023-08-25Actual
Enrollment · participants233Actual
Source updated2024-11-20Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview